First Trust Advisors LP Raises Stake in Bio-Techne Corp $TECH

First Trust Advisors LP lifted its stake in shares of Bio-Techne Corp (NASDAQ:TECH - Free Report) by 2,874.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,281,792 shares of the biotechnology company's stock after purchasing an additional 1,238,705 shares during the quarter. First Trust Advisors LP owned about 0.82% of Bio-Techne worth $66,986,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Danske Bank A S purchased a new stake in Bio-Techne during the fourth quarter worth about $29,000. eCIO Inc. purchased a new position in Bio-Techne in the fourth quarter valued at about $30,000. Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne in the third quarter valued at about $32,000. iSAM Funds UK Ltd acquired a new stake in shares of Bio-Techne during the 3rd quarter valued at approximately $33,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 562 shares during the period. Hedge funds and other institutional investors own 98.95% of the company's stock.

Bio-Techne Stock Down 0.2%

TECH stock opened at $71.60 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.49 and a quick ratio of 3.18. The company's 50 day simple moving average is $60.48 and its 200-day simple moving average is $58.82. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.16. The firm has a market capitalization of $11.21 billion, a PE ratio of 103.77, a P/E/G ratio of 8.53 and a beta of 1.29.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The company had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.11 million. During the same quarter in the prior year, the firm earned $0.56 earnings per share. The company's revenue for the quarter was down 1.5% on a year-over-year basis. Equities analysts expect that Bio-Techne Corp will post 1.65 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were given a dividend of $0.08 per share. The ex-dividend date of this dividend was Monday, May 18th. This represents a $0.32 annualized dividend and a yield of 0.4%. Bio-Techne's dividend payout ratio (DPR) is presently 46.38%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TECH. Royal Bank Of Canada cut Bio-Techne from an "outperform" rating to a "sector perform" rating and upped their price target for the stock from $62.00 to $73.00 in a report on Thursday, July 9th. Zacks Research cut Bio-Techne from a "hold" rating to a "strong sell" rating in a report on Monday, June 8th. Leerink Partners set a $73.00 target price on Bio-Techne in a research report on Thursday, June 25th. Citigroup lowered Bio-Techne from a "buy" rating to a "neutral" rating and upped their target price for the company from $70.00 to $73.00 in a report on Friday, June 26th. Finally, Wells Fargo & Company dropped their price target on Bio-Techne from $76.00 to $62.00 and set an "overweight" rating for the company in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $68.08.

Bio-Techne Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.